Regenerative
One child, 80 months on: gene therapy holds off a fatal brain disease
By John Hyland, . Life and Health Today.
A child with one of the most severe inherited brain diseases on record has now gone 80 months without the biochemical collapse the condition almost always causes, according to a case report published in Molecular Therapy, the American Society of Gene Therapy's journal.
The disease is Mucopolysaccharidosis IIIA, known as MPSIIIA or Sanfilippo syndrome type A. It is caused by a fault in the SGSH gene, which normally produces an enzyme that breaks down a sugar-chain molecule called heparan sulfate. Without that enzyme, heparan sulfate accumulates inside cells, triggering inflammation and cell death in the brain. Children with the condition typically develop normally for the first year or two of life, then lose ground: developmental delay, severe behavioural disturbance and progressive neurodegeneration follow, and most die in their late teens. There is no approved treatment.
The therapy described in Molecular Therapy is called autologous haematopoietic stem cell gene therapy, or HSC-GT. Haematopoietic stem cells are the blood-forming cells in bone marrow; autologous means they came from the patient's own body rather than a donor. Researchers collected those cells from the child's peripheral blood, used a lentiviral vector, a modified virus that carries genetic cargo into cells, to insert a working copy of the SGSH gene, and then infused the corrected cells back after chemotherapy to clear space in the marrow. The investigational product used is identified in the paper as OTL-201. The child was 30 months old at the time of treatment.
The paper reports that the corrected cells engrafted quickly and have continued producing SGSH enzyme at levels above the normal range in white blood cells, plasma and cerebrospinal fluid, the fluid surrounding the brain and spinal cord, for the full 80-month follow-up period. Heparan sulfate levels in urine, plasma and cerebrospinal fluid fell to within the normal range and have stayed there. Neurocognitive assessments using the Bayley Scale of Infant Development, a standardised developmental test, and parent-reported measures showed improvements compared with what the natural history of the disease would predict.
The authors describe the results as demonstrating "sustained long-term efficacy and safety" in this patient, and say the findings set the stage for a clinical trial at phase I/II in younger patients. A phase I/II trial is an early-stage study designed primarily to assess safety and dosing; it is not designed to establish whether a treatment works across a population.
Several things this single case cannot establish are worth stating plainly. One patient is not a trial. The paper does not include a control group, so the comparison to natural history relies on historical data rather than a matched untreated child followed in parallel. The authors do not report the full neurocognitive scores, only that outcomes were better than natural history would predict, so the size of any developmental benefit cannot be assessed from what is published. Long-term safety, including any risk from the lentiviral vector or the chemotherapy conditioning, cannot be fully characterised from one case over 80 months.
What the report does establish is that biochemical correction, meaning normal enzyme levels and normal substrate levels in the right compartments including the brain, is achievable and has held for nearly seven years in this child. That is a meaningful signal in a disease where no such correction has previously been sustained. Whether it translates into preserved cognition and function over a lifetime, and whether it will replicate in other children treated at different ages or with different disease severity, is what the planned clinical trial would need to answer.
For families affected by MPSIIIA, the honest summary is that this is early but substantive evidence that the biology of the approach works in at least one child. Whether it becomes an available treatment depends on what the phase I/II trial finds, and that data does not yet exist. Any decision about participation in a trial belongs with a specialist who knows the individual child's history.
Life & Health Today provides information for educational purposes only, not medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional.